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Abstract
The Centers for Disease Control and Prevention’s Screen for Life: National Colorectal Cancer 
Action Campaign has operated continuously since 1999 to promote colorectal cancer screening. 
The campaign’s most recent formative research cycle was conducted in 2015, and included 16 
focus groups in four U.S. cities with adults aged 50–75 years who had not received colorectal 
cancer screening as recommended. The most common reason for screening non-participation was 
aversion to some aspect of colonoscopy, such as preparation, the invasive nature of the test, or the 
possibility of complications. Other reasons for screening non-participation were absence of 
symptoms, lack of screening awareness/provider recommendation, and lack of family history. 
Screening promotion messages that resonated with participants included: multiple screening tests 
are available; colorectal cancer may not cause symptoms; screening should begin at age 50; and 
most cases of colorectal cancer occur in individuals with no family history of the disease. Efforts 
to increase colorectal cancer screening participation may be supported by disseminating messages 
that counter common concerns about screening. Raising awareness of the range of colorectal 
cancer screening options may be especially critical given that many unscreened individuals were 
unwilling to undergo a colonoscopy.
INTRODUCTION
Colorectal cancer is largely preventable through screening,1 yet it remains the second 
leading cause of U.S. cancer death.2 Among cancers that affect only women, colorectal 
cancer is the third most lethal after lung and breast cancers.2 Only 58.9% of women and 
56.7% of men aged 50–75 years in the United States have been screened with a 
recommended modality3: colonoscopy every 10 years, annual high-sensitivity fecal occult 
blood test (FOBT), or sigmoidoscopy every five years in combination with FOBT every 
three years.4
Corresponding author: Cynthia A. Gelb, Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, 3719 
North Peachtree, MS: F75, Chamblee Building 107, Room 4262, Chamblee, GA 30341, Phone: 770-488-4708, Fax: 770-488-3040, 
cgelb@cdc.gov. 
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention
Conflicts of Interests: The authors have no conflicts of interests to disclose.
HHS Public Access
Author manuscript
J Womens Health (Larchmt). Author manuscript; available in PMC 2018 July 30.
Published in final edited form as:
J Womens Health (Larchmt). 2016 October ; 25(10): 990–995. doi:10.1089/jwh.2016.6049.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
“80% by 2018” is a goal to increase colorectal cancer screening to 80% of eligible adults by 
2018 issued by the National Colorectal Roundtable, an organization cofounded by the 
Centers for Disease Control and Prevention (CDC) and the American Cancer Society.5 To 
promote colorectal cancer screening among the at-risk population, CDC implemented the 
Screen for Life: National Colorectal Cancer Action Campaign (www.cdc.gov/screenforlife), 
which has operated continuously and year-round since 1999.6 The campaign’s most recent 
formative research cycle investigated reasons for screening non-participation among 
individuals who were not up-to-date with screening, as well as messages and creative 
approaches to promote screening.
METHODS
During September and October 2015, CDC conducted 16 focus groups in four U.S. cities—
four groups each in New York City (n=36), Chicago (n=34), Los Angeles (n=35), and Miami 
(n=34) (N=139). Each focus group included 7–9 participants and lasted approximately two 
hours.
The cities where focus groups were held were selected based on their geographic diversity, 
the racial/ethnic diversity of their residents, and the availability of reliable and experienced 
focus group facilities. Participants were recruited using public information (e.g., telephone 
listings) and venues (e.g., city parks), as well as proprietary sources (e.g., lists maintained by 
focus group facilities). Participants were limited to adults aged 50–75 years who had never 
been diagnosed with colorectal cancer or polyps and had not been screened as recommended 
(no colonoscopy within the last 10 years; no FOBT within the last year; and no 
sigmoidoscopy within the last five years in combination with FOBT within the last three 
years). Recruiters evaluated participants’ eligibility based on self-reported data obtained 
using a brief screening questionnaire. Participants included a diverse mix of individuals 
(Table 1).
The focus groups were facilitated by a professional moderator who followed a semi-
structured discussion guide. At the beginning of each focus group, participants were asked 
what they knew about colorectal cancer. If the topics of risk factors and recommended 
screening tests did not come up organically, the moderator raised these topics to investigate 
general colorectal cancer knowledge among participants. The moderator also asked 
participants if they had been screened for colorectal cancer and then why they were not up-
to-date with screening. After this, participants were shown creative concepts for video public 
service announcements. These were formatted as animatics, a series of drawings edited 
together on video, along with a soundtrack of the script read by non-professional actors. 
Prior to showing the creative concept prototypes, the focus group moderator explained their 
unfinished nature and emphasized that any concept, if produced, would flow seamlessly, and 
would include live, professional actors, not drawings.
In total, 11 concepts were tested; however, no more than seven were tested in any city (Table 
2). The order in which concepts were shown was varied in every focus group to counter the 
potential for order effects.7 All focus groups were monitored by at least two on-site 
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observers. Additional observers watched the focus groups remotely via online streaming 
video.
All observers recorded detailed notes. After each city, the lead investigator prepared a 
summary of results, which was then shared with other observers to reach consensus on the 
findings.
RESULTS
Colorectal Cancer Screening Awareness
Many participants indicated that they had received a colorectal cancer screening 
recommendation from their health care provider (Table 2), with colonoscopy being the only 
test recommended to most participants. Accordingly, several participants in every focus 
group said that colonoscopy was a screening test for colorectal cancer. FOBT was mentioned 
by participants in half of the focus groups. No participants mentioned flexible 
sigmoidoscopy as a screening test. A few participants mistakenly believed that the digital 
rectal exam and upper endoscopy screened for colorectal cancer. In most focus groups, 
participants mentioned that screening should begin at age 50. Colorectal cancer risk factors 
mentioned by participants included family history, diet, and age. Participants in every city 
mentioned the term “polyps” before it was introduced by the moderator or the materials 
tested.
Reasons for Screening Non-Participation
The most common reason participants gave for not getting screened for colorectal cancer 
was an aversion to some aspect of colonoscopy, such as preparation, the invasive nature of 
the test, or the possibility of complications. Many colonoscopy-resistant participants lacked 
awareness of alternative screening options, and those who were familiar with other screening 
tests generally believed that colonoscopy was the only worthwhile test. Other participants 
indicated that they had not been screened because they did not know that they should be, or 
because no health care provider had recommended it to them. Many participants also 
indicated that they did not feel that screening was necessary because they had no symptoms 
and were in good health. Some believed they did not need to be screened because they had 
no family history of colorectal cancer. A few participants indicated that the costs and 
logistics (e.g. taking time off from work) associated with colonoscopy prevented them from 
being screened. Several participants were reluctant to see a health care provider under any 
circumstance, and a few indicated that they would prefer to die of cancer without it ever 
being diagnosed. Finally, a few participants attributed their lack of screening to general 
procrastination and laziness.
Messages that Resonated
When asked what messages presented in the creative concepts were compelling, participants 
most often mentioned the availability of several screening options. The existence of 
screening alternatives to colonoscopy was new information to most participants and 
generated a great deal of interest. Other messages frequently mentioned by participants as 
compelling were: screening should begin at age 50; colorectal cancer is the second leading 
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cancer killer; colorectal cancer may not cause symptoms; most colorectal cancers occur in 
individuals with no family history of the disease; and colorectal cancer can be prevented 
through screening.
Creative Elements that Resonated
Several types of appeals were tested, including informational (straightforward, first-person 
presentations), metaphorical (appeals involving analogies, such as comparing caring for 
one’s body to taking care of home maintenance), and role modeling with a positive outcome 
(someone was screened and precancerous polyps were found and removed as a result). Some 
of the creative concepts featured just one individual making a direct appeal, while others 
featured a diverse cast; and some focused on the family as a reason to get tested.
Straightforward, informational appeals were preferred in every focus group. Concepts that 
mentioned the importance of being screened so that one could live to enjoy his or her family 
were also very well received. Concepts with a sad tone, such as those mentioning someone 
dying from colorectal cancer, were polarizing with participants reacting either very 
positively or very negatively. Conversely, broad appeal was achieved by concepts in which 
individuals were screened and precancerous polyps or cancer were caught in time. 
Participants also responded favorably to concepts that featured racially and ethnically 
diverse men and women who role modeled being screened.
DISCUSSION
Efforts to increase colorectal cancer screening rates may be supported by the dissemination 
of screening information in a straightforward, direct manner, which was overwhelmingly 
preferred by focus group participants. Messages that particularly resonated with participants 
countered common reasons for screening non-participation (Table 3).
In contrast to previous research conducted by CDC’s Screen for Life campaign in which 
most participants knew little about colorectal cancer and the need for screening,9 most 
participants in the present study were aware that they should be screened, and many had 
received a colonoscopy referral from their health care provider. In addition, participants in 
the majority of focus groups were largely familiar with the risk factors of colorectal cancer, 
and many knew that screening should begin at age 50. This reflects an important shift in 
consumer knowledge and perceptions about colorectal cancer and screening.
Raising awareness of the range of colorectal cancer screening options may be a critical 
component of screening promotion efforts. Colonoscopy was at the center of an impasse to 
screening for many participants in the present study. Concerns about the preparation, 
invasiveness, and possible complications of colonoscopy were abundant, and many 
participants were resistant to having the procedure. Colonoscopy was the most familiar 
screening option and was usually the only test that participants said that their health care 
provider had recommended. This result is consistent with national screening data; 
colonoscopy is the screening strategy used almost exclusively in the United States.8 
Participants were enthusiastic and intrigued to learn there are screening options other than 
colonoscopy. While FOBT offers a non-invasive screening option, familiarity with FOBT 
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was relatively low, and it was rarely offered to participants by their health care provider. In 
every focus group, several participants expressed an interest in learning more about 
screening options and said they would ask their health care provider about undergoing a 
screening test other than colonoscopy.
The design of the present study does not support gender-specific analyses, as focus groups 
included both men and women and were not stratified by gender. However, women’s reasons 
for non-participation in colorectal cancer screening reported in prior studies10–14—lack of 
awareness, lack of provider recommendation, test invasiveness, fear of pain or discomfort, 
aversion to preparation for endoscopic procedures, low perceived risk, embarrassment, fear 
of complications, fear of test result, cost, and inconvenience—are consistent with the results 
of the present study.
Increasing screening participation in the United States may depend in large part on raising 
awareness that colonoscopy is not synonymous with colorectal cancer screening. Mass 
communication strategies and provider-patient communication can work in tandem to 
disseminate this message. Providers should offer patients the range of recommended 
screening options and should recommend colorectal cancer screening opportunistically, 
when patients visit for any reason.
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Table 1
Participant characteristics (N=139)
Characteristic n %
Location
 New York City 36 25.9
 Chicago 34 24.5
 Los Angeles 35 25.2
 Miami 34 24.5
Gender
 Male 68 48.9
 Female 71 51.1
Age (years)
 50–54 46 33.1
 55–59 47 33.8
 60–64 31 22.3
 65–75 15 10.8
Race/ethnicity
 Caucasian 59 42.4
 African-American 49 35.3
 Hispanic 21 15.1
 Asian 10 7.2
Educational attainment
 < High school 0 0.0
 High school 31 22.3
 Some college 44 31.7
 College degree 41 29.5
 Advanced degree 23 16.5
Income
 ≤$60K 74 53.2
 >$60K 65 46.8
Employment
 Full-time 75 54.0
 Part-time 33 23.7
 None/retired 31 22.3
Health insurance
 Yes 117 84.2
 No 22 15.8
Last routine check-up
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Characteristic n %
 Within last year 99 71.2
 2–3 years 26 18.7
 4 years or longer 14 10.1
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Table 3
Colorectal cancer screening promotion messages that counter common screening concerns
Screening concerns Counter message
Aversion to colonoscopy Multiple screening tests are available.
Absence of symptoms Colorectal cancer may not cause symptoms.
Lack of awareness in general or provider 
recommendation
Screening should begin at age 50.
Lack of family history Most cases of colorectal cancer occur in individuals with no family history of the 
disease.
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